On June 27th, Gelonhui announced that leading healthcare AI company, Medbanks Technology (2158.HK), released its fiscal year 2024 performance. During the reporting period, Medbanks Technology achieved a revenue of RMB 807 million, with gross margin rising from 34.1% in the same period last year to 42.1%, an increase of 8 percentage points, setting a new historical high. Adjusted net loss for the year decreased significantly by 64.8% to RMB 158 million, compared to approximately RMB 449 million in fiscal year 2023. In the fiscal year 2024, Medbanks Technology focused on its core business, concentrating on improving internal operating efficiency and profitability. The big data platform and solution segment generated revenue of approximately RMB 314 million during the fiscal year, a year-on-year increase of 41.4%. The life science solution segment had revenues of RMB 324 million, a year-on-year increase of 28.1%, with gross margin rising 14.6 percentage points to 32.1%, achieving a new historical high. The health management platform and solution segment netted approximately RMB 170 million in revenue, with a gross margin of 58.1%, representing an increase of 17.4 percentage points year-on-year. During the reporting period, Medbanks Technology continued its research and training in the medical vertical domain large language model based on a corpus of 500 billion professional training tokens, and completed the training of models with 6B, 13B and 70B parameters. In addition, Medbanks Technology's large model has been listed with the National Network Information Office's algorithm filing. In May 2024, the large model of Medbanks Technology ranked first in the authoritative evaluation of MedBench, launched by Shanghai AI Laboratory and the Shanghai Digital Medical Innovation Center, in the three key dimensions of medical knowledge questioning, medical language understanding, and medical safety and ethics, with an overall comprehensive score ranking first. Meanwhile, Medbanks Technology is actively and rapidly promoting the implementation of large models. On the one hand, Medbanks Technology empowers its existing product matrix and application solutions by upgrading them with the large model. For example, Medbanks Technology's existing scientific research platform product can shorten the traditional research cycle of 6-12 months to 2-6 months. After being empowered by the large model, the scientific research platform product can speed up by an additional 50%, further consolidating its market position of being a leading clinical research brand. On the other hand, Medbanks Technology continues to innovate large model applications. Based on Medbanks Technology's large model, the private health advisor "XinKang Health Technology" mini-program has been launched, which is deeply integrated with the company's "HuiMinBao" business and provides exclusive services such as health records and health follow-up to more than 5 million participants in the "Jiangsu Yi Hui Insurance No. 1" program.